What is a stock summary page? Click here for an overview.
Business Description
Innate Pharma SA
NAICS : 325412
SIC : 2834
ISIN : FR0010331421
Share Class Description:
LTS:0EVI: Class ACompare
Compare
Traded in other countries / regions
IPH.FranceIPHA.USA0EVI.UKIDD.GermanyIPH.Switzerland IPO Date
2013-04-23Description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.59 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 1.23 | |||||
| Debt-to-EBITDA | -1.19 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -0.98 | |||||
| Beneish M-Score | -1.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.2 | |||||
| 3-Year FCF Growth Rate | 18.4 | |||||
| 3-Year Book Growth Rate | -31.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 46.21 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.96 | |||||
| 9-Day RSI | 34.56 | |||||
| 14-Day RSI | 40.76 | |||||
| 3-1 Month Momentum % | 13.45 | |||||
| 6-1 Month Momentum % | 7.02 | |||||
| 12-1 Month Momentum % | -0.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.92 | |||||
| Quick Ratio | 2.92 | |||||
| Cash Ratio | 2.4 | |||||
| Days Sales Outstanding | 348.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 2.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -155.26 | |||||
| Net Margin % | -137.03 | |||||
| FCF Margin % | -82.02 | |||||
| ROE % | -73.73 | |||||
| ROA % | -19.1 | |||||
| ROIC % | -50.74 | |||||
| 3-Year ROIIC % | 18.28 | |||||
| ROC (Joel Greenblatt) % | -227.75 | |||||
| ROCE % | -23.12 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 29.62 | |||||
| PS Ratio | 6.05 | |||||
| PB Ratio | 5.24 | |||||
| Price-to-Tangible-Book | 5.33 | |||||
| EV-to-EBIT | -3.14 | |||||
| EV-to-EBITDA | -3.42 | |||||
| EV-to-Revenue | 4.09 | |||||
| EV-to-Forward-Revenue | 4.8 | |||||
| EV-to-FCF | -4.97 | |||||
| Price-to-GF-Value | 0.59 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | -31.84 | |||||
| FCF Yield % | -12.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Innate Pharma SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 24.85 | ||
| EPS (TTM) (€) | -0.42 | ||
| Beta | 0.51 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.11 | ||
| Volatility % | 24.61 | ||
| 14-Day RSI | 40.76 | ||
| 14-Day ATR (€) | 0.060822 | ||
| 20-Day SMA (€) | 1.999375 | ||
| 12-1 Month Momentum % | -0.23 | ||
| 52-Week Range (€) | 1.353 - 2.79 | ||
| Shares Outstanding (Mil) | 83.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innate Pharma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innate Pharma SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Innate Pharma SA Frequently Asked Questions
What is Innate Pharma SA(LTS:0EVI)'s stock price today?
The current price of LTS:0EVI is €1.87. The 52 week high of LTS:0EVI is €2.79 and 52 week low is €1.35.
When is next earnings date of Innate Pharma SA(LTS:0EVI)?
The next earnings date of Innate Pharma SA(LTS:0EVI) is 2025-03-27.
Does Innate Pharma SA(LTS:0EVI) pay dividends? If so, how much?
Innate Pharma SA(LTS:0EVI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers